DME patient treated with Iluvien

Article

Iluvien has been used to treat a diabetic macular oedema (DME) patient in the UK since the product became commercially available, it was revealed in a press release this week.

Iluvien has been used to treat a diabetic macular oedema (DME) patient for the first time since the product became commercially available, it was revealed in a press release this week.

Alimera Sciences announced the 190 micrograms intravitreal implant, approved for use in six European countries, was inserted in a 67-year-old man who has suffered diabetes for over 20 years.

Each implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). Iluvien is administered via an applicator that consists of a 25G needle, allowing for a self-sealing wound.

Professor Albert J. Augustin, professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Germany and a member of OTEurope's EAB, commented, “We are honoured to be the first hospital to offer this new sustained release treatment to those suffering from vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Iluvien brings hope to many patients in Germany affected by this sight-robbing disease.”

Dan Myers, president and CEO of Alimera, stated, “Now chronic DME patients in both Germany and the UK have a long-acting, sustained release treatment option available to help improve their visual acuity.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.